Robert D. Schouten - Concepedia

Concepedia

Author

Robert D. Schouten

The Netherlands Cancer Institute ORCID

Also Known As

R. D. Schouten, R. Schouten, R.D. Schouten, Robert D Schouten, Robert D. Schouten, Robert Schouten

42

Publications

1.9K

Citations

11

H-Index

17

Concepts

All Affiliations

The Netherlands Cancer Institute Radboud University Nijmegen Radboud University Medical Center University of Lucerne University of Amsterdam

RD

About

Robert D. Schouten is an author at The Netherlands Cancer Institute specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.5K
2	Pathology	3	3	1.4K
3	Immunology	2	2	1.4K
4	Health Sciences	1	1	41
5	Cancer Epidemiology	1	1	54

Robert D. Schouten

×

10

Publications

1.9K

Citations

10

H-Index

	Year	Citations
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J. Mazieres, Alexander Drilon, Amélie Lusque, Annals of Oncology Advanced Lung CancerCancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsImmunology	2019	1.3K
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma Josine M.M.F. Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries, Journal of Thoracic Oncology	2018	244
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath R. de Vries, Mirte Muller, Vincent van der Noort, Annals of Oncology	2019	76
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). Julien Mazieres, Alexander Drilon, Laurent Mhanna, Journal of Clinical Oncology ImmunologyPathologyImmunotherapyTumor BiologyOncology	2018	54
OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies Josine M.M.F. Quispel-Janssen, Giulia Zago, Robert D. Schouten, Journal of Thoracic Oncology Malignant Pleural MesotheliomaMedicinePathologyTranslational ResearchPleural Disease	2017	52
Real life experience with nivolumab for the treatment of non-small cell lung carcinoma Robert D. Schouten, Mirte Muller, Cornedine J. de Gooijer, Lung Cancer OncologyHealth SciencesImmune Checkpoint InhibitorBronchial NeoplasmCancer Treatment	2017	41
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Clinical Cancer Research	2022	41
Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer Robert D. Schouten, Daan C.L. Vessies, Linda J.W. Bosch, JCO Precision Oncology	2021	14
An Automated Correction Algorithm (ALPACA) for ddPCR Data Using Adaptive Limit of Blank and Correction of False Positive Events Improves Specificity of Mutation Detection Daan C.L. Vessies, Theodora C. Linders, Mirthe Lanfermeijer, Clinical Chemistry	2021	12
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care Robert D. Schouten, Lucie Egberink, Mirte Muller, Translational Lung Cancer Research	2020	11

Page 1